Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments

NCT04640077 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04640077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04640077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 23, 2020
Completion date
February 27, 2024
Enrollment
95 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, brain diseases, central nervous system diseases, cognitive impairment, dementia